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Abstract 
 
Objectives: The current paper examines prevalence of cognitive impairment in four mood 
disorder samples, using four definitions of impairment. The impact of premorbid IQ on 
prevalence was examined, and the influence of treatment response.  
 
Methods: Samples were: 1) 58 inpatients in a current severe depressive episode (unipolar or 
bipolar), 2) 69 unmedicated outpatients in a mild to moderate depressive episode (unipolar or 
bipolar), 3) 56 outpatients with bipolar disorder, in a depressive episode, and 4) 63 
outpatients with bipolar disorder, currently euthymic. Cognitive assessment was conducted 
after treatment in Studies 1 (six weeks of antidepressant treatment commenced on admission) 
and 2 (16-week course of cognitive behaviour therapy or schema therapy), allowing the 
impact of treatment response to be assessed. All mood disorder samples were compared with 
healthy control groups.  
 
Results: Prevalence of cognitive impairment was highest for the inpatient depression sample, 
and lowest for the outpatient depression sample. Substantial variability in rates were observed 
depending on the definition of impairment used. Correcting cognitive performance for 
premorbid IQ had a significant impact on the prevalence of cognitive impairment in the 
inpatient depression sample. There was minimal evidence that treatment response impacted 
on prevalence of cognitive impairment, except in the domain of Psychomotor Speed in 
inpatients.  
 
Conclusions: As interventions aiming to improve cognitive outcomes in mood disorders 
receive increasing research focus, the issue of setting a cut-off level of cognitive impairment 
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for screening purposes becomes a priority. This analysis demonstrates important differences 
in samples likely to be recruited depending on the definition of cognitive impairment and 
begins to examine the importance of premorbid IQ in determining who is impaired.  
 
 
Key words: Cognitive Impairment; Memory; Depression; Bipolar Disorder; 
Neuropsychology; Prevalence 
  
4 
 
Introduction 
Cognitive impairment is a core feature of bipolar disorder and recurrent major depressive 
disorder (MDD) (1-4), is associated with difficulties in occupational and interpersonal 
functioning (5, 6), and thus has a major impact on depressed individuals’ quality of life. First-
line antidepressant and psychological treatments have limited beneficial impact on cognitive 
functioning and deficits persist into recovery (1, 3, 7-10). It is therefore crucial to focus not 
only on clinical outcomes in mood disorder intervention studies, but also cognitive and 
functional outcomes.  
 
On the basis of a moderate to large effect size difference in group means between bipolar or 
MDD patients, and healthy controls, it has sometimes been assumed that those with mood 
disorders may all benefit from interventions specifically to improve cognition. However, 
studies have suggested that only a percentage of depressed patients (unipolar or bipolar), or 
euthymic bipolar disorder patients, show significant cognitive impairment, when judged by 
usual criteria of difference from a normative group mean by number of standard deviations 
(SD) (11-13). This has important implications for treatment and for screening for inclusion in 
studies which aim to improve cognitive function. Inclusion of a number of depressed 
individuals with unimpaired cognitive function may wash out any positive effect and result in 
failed trials (14, 15). Screening has recently been recommended by a task force of the 
International Society for Bipolar Disorders (16). If meaningful screening thresholds can be 
identified, this may prove beneficial in identifying those who could benefit from specific 
interventions.  
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Few studies have examined prevalence rates of cognitive impairment in mood disorder 
samples. Gualtieri and Morgan (13) examined rates in outpatient samples with bipolar 
disorder (I and II) and MDD. Using their conservative criteria of cognitive impairment (two 
or more cognitive domains impaired more than two SD below norms for healthy controls), 
they showed that 20 to 30% of those with bipolar disorder or MDD were impaired. Iverson 
and colleagues (12) studied prevalence rates of cognitive impairment in three different 
outpatient mood disorder samples (bipolar disorder, unmedicated MDD, and medicated 
MDD) who completed the same cognitive testing battery as in Gualtieri and Morgan (13) 
(CNS Vital Signs). Having two or more cognitive domain scores more than 1.5 SD below the 
control norm was suggested as a criterion for identifying significant cognitive impairment, 
based on low false positive rates (i.e., this classified a low percentage of the healthy control 
participants as impaired). Other approaches to defining cognitive impairment have been 
proposed outside mood disorder research, including examination of scores on individual 
cognitive test variables (e.g., greater than 1.5 or 2 SD below healthy controls on two or more 
cognitive test variables) or using a specified global cognitive composite (e.g., greater than 1.5 
or 2 SD on a global cognitive composite). Overall, however, there is little consensus 
regarding how to define cognitive impairment in mood disorder research or what useful 
thresholds would be. 
 
Premorbid IQ is an important and often neglected factor that should be taken into account 
when assessing degree of cognitive impairment. Individuals with a premorbid IQ of one or 
more SD below the population mean will, by definition, show results of at least one SD 
below the mean on several cognitive tests, and would therefore be defined as being 
‘cognitively impaired’ if a threshold of one SD was set. Thus, while some individuals in 
studies of mood disorders may have illness-related cognitive impairment, others’ cognitive 
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impairment may simply be as a result of low premorbid cognitive function. In contrast, those 
with a premorbid IQ of one or more SD above the population mean are very unlikely to be 
detected as ‘impaired’ even if their performance is substantially lower than the level their 
premorbid IQ would predict. Variability in cognitive performance in mood disorder samples 
(4, 17) may be, in part, due to these individual differences in mechanisms underlying 
cognitive impairment. For the above reasons, it would therefore be of use to determine 
whether measures of premorbid IQ could be used to increase the accuracy of definition of 
cognitive impairment in mood disorder samples. 
 
The current study aims to replicate and extend results of studies examining the prevalence of 
cognitive impairment in mood disorder samples (11-13). Findings will be presented from four 
well-defined mood disorder samples: inpatient depression, medication-free outpatient 
depression, bipolar depression, and euthymic bipolar disorder. Group comparisons with 
healthy controls for all four samples have been reported previously (18-21), but prevalence 
rates of cognitive impairment, as analysed here, have not been examined. Cognitive 
impairment will be defined according to: 
1. deviation from controls on pre-defined domains of cognitive functioning by 
examining 
a. the number of domains impaired and 
b. the type of domains impaired, 
2. deviation from controls on a number of individual test variables, and 
3. deviation from controls on a global cognitive composite score.  
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Further analysis will correct the global cognitive composite scores for premorbid IQ. As far 
as we are aware, this is the first study in mood disorder samples which specifically 
determines the impact of premorbid IQ on prevalence of cognitive impairment at an 
individual level. Previous studies have tended to focus on the protective impact of premorbid 
IQ or cognitive reserve on cognitive functioning, for example, in bipolar disorder (22) and in 
depressed individuals receiving electroconvulsive therapy (23).  
 
In two studies (inpatient and outpatient depression samples), depressed and healthy control 
groups underwent treatment and completed follow-up cognitive testing. Thus, the first three 
analyses above were repeated on follow-up data and assessed in relation to treatment 
response.  
 
Methods 
The first two samples presented in this paper completed cognitive assessment at two time-
points.  To ensure accurate comparison of prevalence rates across time-points, only 
participants who completed baseline and follow-up cognitive assessment are included in this 
paper.  
 
All studies used the Structured Clinical Interview for DSM–IV Axis I Disorders (SCID–I) 
(24) to confirm mood disorder diagnosis. At least one widely-used mood rating scale 
(Montgomery-Asberg Depression Rating Scale, MADRS (25); 17-item Hamilton Depression 
Rating Scale, HDRS-17 (26); and Young Mania Rating Scale, YMRS (27)) was administered 
in all studies to assess severity of mood symptoms. Exclusion criteria for depressed and 
healthy control groups for Studies 1, 2 and 4 were: schizophrenia, current serious alcohol or 
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drug misuse or dependence, comorbid endocrinological, neurological or chronic medical 
conditions, pregnancy, previous serious head injury, electroconvulsive therapy (ECT) in the 
past 12 months, or taking medications likely to interfere with cognitive functioning. For 
Study 3, current serious alcohol or drug misuse or dependence was the only exclusion 
criterion. Healthy control groups for all studies consisted of age- and gender-matched 
psychologically healthy individuals without a personal history, or a history in a first-degree 
relative, of major mental illness.  
 
Study 1: Inpatient Depression Sample 
Study Design 
Cognitive functioning in depressed participants was assessed within two days of admission 
(baseline) to an acute psychiatric inpatient ward in Christchurch, New Zealand, and six weeks 
after baseline. Treatment was naturalistic, with inpatients receiving standard care. Healthy 
control participants completed cognitive assessment at the same time-points.   
 
Participants 
Fifty-eight inpatients aged between 18 and 60 years, with a primary DSM-IV (28) diagnosis 
of major depressive episode (MDE; unipolar, n = 50 or bipolar, n = 8), completed both 
clinical and cognitive assessments. At baseline, 19 participants were unmedicated and 
subsequently commenced on an antidepressant medication. Of the remaining participants (n = 
39), the dose of their existing antidepressant was increased or they were changed to another 
antidepressant medication (see Douglas et al., 2011, for a detailed report of antidepressant use 
in the depressed group). No significant differences between medicated and unmedicated 
patients were observed on any cognitive variables at baseline. At follow-up, all were 
medicated with an antidepressant, the vast majority with a selective-serotonin reuptake 
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inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI). Participants were 
classified according to treatment response at the six-week follow-up (treatment response ≥ 
50% reduction in MADRS score from baseline to follow-up). The healthy control group 
consisted of 50 individuals, who were screened for current and past psychiatric conditions 
using the Mini International Neuropsychiatric Interview (MINI) (29). See Douglas et al. (18) 
for main cognitive outcome data and additional study information. 
 
Study 2: Outpatient Depression Sample 
Study Design 
Participants were enrolled in a randomised controlled trial (RCT) comparing the effectiveness 
of Cognitive Behaviour Therapy (CBT) with Schema Therapy (ST) for major depression (see 
Carter et al. (30) for main clinical outcomes). Cognitive functioning was assessed prior to 
randomisation (baseline) and after the first 16 weeks of psychological therapy.  
 
Participants 
Sixty-nine depressed outpatients, aged between 18 and 65 years, with a DSM-IV defined 
MDE without psychotic features (single or recurrent major depressive disorder, n = 64 or 
bipolar II depression, n = 5) completed both cognitive assessments. The depressed sample 
was psychotropic-medication-free for at least six weeks prior to recruitment and remained 
medication-free at follow-up. The definition of treatment response was the same as Study 1. 
Fifty-eight healthy control participants (screened using the MINI), completed both cognitive 
assessments. Cognitive data from this sample has been published previously for baseline (19) 
and longitudinal findings (9). 
 
Study 3: Bipolar Depression Sample 
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Study Design 
Depressed participants were part of an RCT investigating the long-term efficacy of 
mifepristone as an adjunctive treatment for bipolar depression. Patients were randomised to 
receive mifepristone or placebo for one week and were followed up for seven weeks 
following treatment cessation. Cognitive assessment occurred prior to randomisation 
(baseline), and 8 weeks after baseline.  
 
Participants 
Fifty-six depressed individuals with a DSM-IV diagnosis of bipolar disorder I or II, current 
episode depressed, completed cognitive assessment. Patient medication was unchanged for 
four weeks prior to participation. Fifty-three healthy controls completed a single cognitive 
assessment. Cognitive outcome data from this study are published in Watson et al. (20). 
 
Study 4: Euthymic Bipolar Disorder Sample 
Study Design 
This was a cross-sectional study of cognitive functioning in prospectively-verified euthymic 
individuals with bipolar disorder. One cognitive assessment was conducted for both euthymic 
bipolar disorder and healthy control participants.  
 
Participants 
Sixty-three outpatients with a DSM-IV diagnosis of bipolar disorder (I and II) completed 
cognitive assessment. Euthymia was confirmed prospectively, with scores below seven on the 
HDRS-17 and YMRS over a period of one month required prior to study entry. With the 
exception of three participants with bipolar disorder who were taking no medication, all were 
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stabilised on prophylactic medication. There were 63 individuals in the healthy control group. 
Cognitive outcome data from this sample have been published in Thompson et al. (21). 
 
Cognitive Testing 
Cognitive tasks used and variables reported across the four samples are displayed in Table 1. 
For an explanation of the cognitive tests and testing conditions (e.g. time of day, computer 
software), see original cognitive outcome papers from these studies (9, 18-21). 
 
**INSERT TABLE 1 ABOUT HERE** 
 
Statistical Analysis 
Statistical analyses were conducted using SPSS, version 22-x for Windows (31). All 
cognitive variables and IQ scores were normally distributed. For demographic and clinical 
characteristics, categorical variables were analysed with χ2 tests and continuous variables 
with independent sample t-tests.  
 
For each of the four studies, mean scores and SD from cognitive and IQ variables in the 
healthy control group at baseline were calculated. Z-scores for depressed and control samples 
for each of these variables were then calculated using the following equation: (raw score – 
meancontrol group)/SDcontrol group. For Studies 1 and 2, both of which had follow-up cognitive data 
in depressed and control groups, this procedure for calculating Z-scores was repeated using 
mean scores of the control participants at follow-up. Z-scores were calculated so that a 
positive Z-score always represented an individual performing more poorly than the mean of 
the healthy control group, regardless of whether the cognitive variable produced outcomes of 
accuracy, number of errors or reaction time.  
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For each study, cognitive variables were grouped to fit into one of four cognitive domains: 1) 
verbal learning and memory, 2) visuospatial learning and memory, 3) executive 
function/attention, and 4) psychomotor speed. Domain scores were calculated by averaging 
the Z-scores of tests within each domain. A Global Cognitive Composite was created by 
averaging Z-scores across the four domain scores from the cognitive testing battery for each 
study.  
 
Four approaches to defining cognitive impairment were used.  
1. Number of cognitive domains impaired: for ease of comparison with previous studies 
in this area (12, 13), performance was evaluated as the number of cognitive domains 
in which participants scored below healthy controls by 1, 1.5 and 2 SD. Three SD cut-
offs were included because there is no consensus regarding an ideal cut-off, with 
some studies in mood disorder samples suggesting a conservative cut-off of 2 SD 
below ‘normal’ (13) as reflecting meaningful cognitive impairment, and other studies 
suggesting less-conservative cut-offs of 1 or 1.5 SD (12, 32, 33).  
2. Percentage of depressed participants impaired in each cognitive domain: in order to 
examine whether specific cognitive domains had higher prevalence rates of 
impairment, the percentage of participants impaired at 1, 1.5 and 2 SD cut-offs on 
each cognitive domain was calculated for depressed participants and healthy controls.  
3. Global Cognitive Composite: the prevalence of cognitive impairment when using the 
Global Cognitive Composite was assessed in depressed and healthy control groups, at 
1, 1.5 and 2 SD cut-offs. 
4. Number of test variables impaired: a commonly cited approach to categorising 
cognitive impairment involves determining the percentage of depressed participants 
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impaired on a certain number of individual test variables. In the present study, the 
percentage of participants impaired (1, 1.5 and 2 SD cut-offs) on at least two 
individual cognitive variables from different tasks (for example, impairment on 
RAVLT total learning and RAVLT delayed recall did not constitute two cognitive 
variables because of the close relationship between these measures) was examined.  
 
The above four approaches were repeated with follow-up data for Studies 1 and 2 for 
treatment responders, non-responders and healthy controls. Statistical comparisons between 
responders and non-responders were conducted using Mann-Whitney U tests (for approaches 
1 and 2 above) or χ2 tests (for approaches 3 and 4 above). Change in prevalence rates 
(comparison of single values or spread of rates, depending on the approach) of cognitive 
impairment in healthy control groups from baseline to follow-up was assessed using 
McNemar tests or paired t-tests (Wilcoxon Signed Rank Test).  
 
The influence of premorbid IQ (from National Adult Reading Test (NART) (34) scores) on 
cognitive performance was taken into account by re-analysing the Global Cognitive 
Composite scores from each study. For each individual, the Z-score for premorbid IQ was 
subtracted from the Z-score for the Global Cognitive Composite. For example, if an 
individual was 1 SD worse than healthy controls on both their premorbid IQ and overall 
cognitive performance, their corrected score of 0 would reflect this balance. However, if an 
individual performed 1 SD worse than healthy controls on overall cognitive performance but 
had an IQ of 0.5 SD better than healthy controls, the cognitive score was corrected by 
reducing it to 1.5 SD worse than controls (corrected z-score = - 1.5) to reflect this 
discrepancy. Percentage of depressed individuals who were impaired at 1, 1.5 and 2 SD cut-
offs on the IQ-corrected Global Cognitive Composite was then calculated for each study.  
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Results 
Demographic details are presented in Table 2. No significant differences between depressed 
and healthy control groups were found for gender, age, number of years of formal education, 
or premorbid IQ (NART).  
 
** INSERT TABLE 2 ABOUT HERE ** 
 
Table 3 presents clinical data from the four samples. Missing scores on measures in Table 3 
is due to differences in clinical data collected between studies. The inpatient depression 
sample was severely depressed at baseline assessment, with an average MADRS score of 
35.7. Scores from the MADRS and HDRS-17 in outpatient depressed and bipolar depressed 
samples indicated moderate depression severity, and the euthymic bipolar sample (who were 
excluded if they were depressed) scored in the normal range on the HDRS-17.  
 
** INSERT TABLE 3 ABOUT HERE ** 
 
Baseline Prevalence of Cognitive Impairment  
Prevalence rates of cognitive impairment using four approaches to define impairment, are 
presented in Table 4. Regarding the number of cognitive domains impaired (first approach), 
most healthy control participants were not impaired on any cognitive domains at 1.5 SD (82-
94%) and 2 SD (92-97%) cut-offs. Participants with mood disorders, particularly the inpatient 
depressed sample, were generally impaired on a greater number of cognitive domains than 
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healthy controls. For example, at the 1.5 SD cut-off, 37.5% of the inpatient depression 
sample (Study 1) were impaired in two or more cognitive domains, while in Studies 2 to 4, 9-
21% of patients were impaired. 
 
The percentage of patients categorised as cognitively impaired on each cognitive domain 
(second approach) varied widely between studies, and within cognitive domains. For healthy 
control groups across studies, prevalence rates of cognitive impairment at the 1.5 SD cut-off 
were all less than 8%, and less than 5% for the 2 SD cut-off. The domain of Verbal Learning 
and Memory had the highest prevalence of impairment in the three samples of participants 
who were currently depressed (17.4 to 36.2% at the 1.5 SD cut-off; Study 1-3). A clear 
profile of impairment when examining patterns across all cognitive domains, using this 
method, was not evident.   
 
Prevalence of impairment on a Global Cognitive Composite (third approach) was low in 
healthy control groups from all studies (e.g., impaired by > 1.5 SD = 0-1.9%; impaired by > 2 
SD, all = 0%). For patient groups, prevalence rates at the 2 SD cut-off were also low (0-
7.5%). 18.9% of the inpatient depression sample were impaired at the 1.5 SD cut-off, 
compared with only 2.9% of the outpatient depression sample. Both bipolar samples had 
similar rates of cognitive impairment at the 1.5 SD cut-off (12.5-14.3%).  
 
Prevalence rates from the final method of defining cognitive impairment, which calculated 
the percentage of participants impaired on at least two individual test variables, are shown in 
Table 4, and discussed further below.  
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** INSERT TABLE 4 ABOUT HERE ** 
 
Prevalence of Cognitive Impairment Corrected for Premorbid IQ 
Global Cognitive Composite scores, corrected for premorbid IQ, for each mood disorder 
sample are presented in Figure 1. Prevalence rates of cognitive impairment for the 1.5 SD 
cut-off increased for Study 1 and 2 when premorbid IQ was taken into account. The increase 
was significant for the inpatient depression sample (Study 1; increased from 18.9 to 41.5%; χ2 
= 4.1, p = 0.04). Five percent of inpatients (3 of 58 participants) moved from being defined as 
cognitively impaired to unimpaired after correction for premorbid IQ, while 28% (16 of 58 
participants) moved from being unimpaired to impaired. Of the 16 individuals who were 
identified as impaired following correction for premorbid IQ, 15 had above average (> 100) 
premorbid IQ scores. Prevalence rates remained similar after adjusting for premorbid IQ in 
the bipolar samples (Study 3 and 4).  
 
** ADD FIGURE 1 ABOUT HERE ** 
 
Prevalence of Cognitive Impairment in Relation to Treatment Response 
Table 5 presents the same four approaches to determining prevalence rates of cognitive 
impairment using follow-up data. In Study 1, prevalence of cognitive impairment in the 
domain of Psychomotor Speed was significantly greater in treatment non-responders 
compared with treatment responders at follow-up (e.g., 1.5 SD = 0.0% vs 18.2%; 2 SD = 
0.0% vs 3.0%: p=0.01). No significant differences between treatment responders and non-
responders were found for any other comparisons from the four approaches to classifying 
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cognitive impairment (all p ≥ 0.05) in either inpatient or outpatient depression samples. 
Prevalence of cognitive impairment in the healthy control samples between baseline and 
follow-up did not differ significantly using any approach (all p ≥ 0.1). 
 
** ADD TABLE 5 ABOUT HERE ** 
 
Discussion 
Prevalence of Cognitive Impairment in Mood Disorders 
Due to differences in cognitive testing batteries and demographic characteristics, the current 
study cannot accurately compare prevalence rates between the four samples. However, it does 
give an indication of the percentage of participants in each sample who would be classified as 
impaired and who might therefore be eligible for treatment studies of cognitive impairment 
depending on the method of enrichment used and the sample being recruited.  
 
The four approaches used to define cognitive impairment resulted in very different 
prevalence rates. The method of categorising cognitive impairment based on the percentage 
of participants impaired on a certain number of individual test variables proved problematic. 
Part of the definition of mild cognitive impairment in Alzheimer’s Disease research is that 
scores on one or more individual test variables should be at least 1 SD below the mean for 
their age (35). Of course, 16% of healthy individuals will score more than 1 SD below the 
norm on a single cognitive test (12), and thus, it was decided that scores on at least two 
different cognitive tests should be impaired for the classification used here. This definition 
has been used recently in a clinical trial of a cognitive remediation intervention in bipolar 
disorder, screened for objective cognitive impairment (36). However, this definition of 
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impairment appeared to be influenced by the number of tests in the cognitive testing battery. 
That is, in the study that included the most cognitive tests (Study 4), a high prevalence of 
patients (78%), and more unusually, healthy controls (49%), were categorised as impaired. In 
comparison, rates of impairment in other healthy control samples ranged from 13 to 26% at 
the same cut-off. This approach may be of more use across studies in similar clinical 
populations using identical cognitive testing batteries.  
 
The method of determining the number of cognitive domains impaired (with no focus on the 
type of cognitive domain), has been examined previously in depressed samples. Cut-offs of 
1.67 SD and 2 SD, on two or more cognitive domains, have been suggested since this gives 
low false positive rates (i.e., low rates for healthy control groups). Using the 2 SD cut-off, 
Gualtieri and Morgan (13) found that 21% of their MDD sample and 30% of their bipolar 
disorder sample were impaired on at least two domains, compared with 3.6% of healthy 
controls. In the current sample, using the same criteria, a lower rate of impairment was found; 
ranging from 4.4% (outpatient depression sample) to 14.3% (inpatient depression sample). 
These lower rates are of note since the inpatient sample in the current study was likely to be 
much more severely depressed than the outpatient samples from Gualtieri and Morgan’s 
study (although mood rating scales were not used in that study). The cognitive testing battery 
completed by the inpatient depressed sample in the current study was brief because of the 
severity of depression. This briefness may have come at the expense of being sensitive to 
cognitive impairment and also of having a reliable representation of the specified cognitive 
domain. Lower prevalence of cognitive impairment in comparison with Gualtieri and 
Morgan’s study in our three outpatient samples (Studies 2-4) may be explained by our 
samples being less severely depressed.  
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This paper does not directly compare matched samples of patients with bipolar disorder and 
unipolar MDD. For example, the samples consisting of patients who were in mood episode 
(Studies 1-3) were not matched for severity or treatment. Therefore, rates of impairment in 
bipolar depression cannot be compared usefully with those in unipolar depression. We also 
note that in Studies 1 and 2, the small percentage of patients with bipolar depression (Study 1 
= 13.8% bipolar depression, Study 2 = 7.2%) meant that a separate analysis to compare rates 
of impairment in bipolar and unipolar depressed patients was not warranted. In these two 
studies, we have previously reported results of re-analyses of main cognitive measures that 
omitted bipolar patients, with these re-analyses not changing results significantly in terms of 
p-values or effect size differences (18, 19).  
 
A less commonly used approach for defining cognitive impairment is to examine rates of 
impairment for each cognitive domain. In the current study, large variability in rates of 
impairment was seen between cognitive domains. The domain of Verbal Learning and 
Memory produced the highest rates of impairment in three of the samples (17-36% 
impairment at 1.5 SD cut-off), however, variability between rates of impairment in other 
cognitive domains made it difficult to determine meaningful patterns. Cullen et al. (11), in 
their review of euthymic bipolar samples, found substantial variability in rates of impairment 
within cognitive domains, which they attributed to small sample sizes and mixed study 
designs. Regardless of these mixed findings, the profile of impairment across cognitive 
domains is important to consider. Significant impairment on a single cognitive domain may 
still impact on general functioning in tasks related to this domain, and if looking only at 
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global cognitive functioning, marked impairment on one domain may be diluted to the extent 
that impairment is no longer evident.  
 
This dilution of any marked impairment on a single domain was indeed observed when using 
a Global Cognitive Composite score from each cognitive testing battery to define 
impairment. This approach resulted in generally lower rates of cognitive impairment (range 
over the four samples at the 1.5 SD cut-off = 1.6 to 18.9%) compared with other approaches, 
which, as suggested previously, was likely due to a flattening out of variability in areas of 
strengths and weaknesses in cognitive domains for each individual. An advantage of this 
approach, however, was that it was simplest to calculate and interpret prevalence rates of 
impairment.  
 
Global Cognitive Composite data illustrated a potential methodological weakness of all four 
studies reported in the current paper. While the distributions of cognitive scores in control 
participants did not depart significantly from normal, in a perfectly normal distribution, the 
rate of impairment in the healthy control groups should have been 6.7%. The actual result in 
the combined control group was 1%. This skew may arise from the fact that people with a 
perception that they have cognitive impairment are unlikely to volunteer to take part in a 
study involving cognitive testing, thereby giving rise to an attenuated tail in the distribution.  
 
The current paper reported prevalence of cognitive impairment based on pre-selected, 
mathematical cut-off points that have been used previously in mood and neurological 
disorder research. True cognitive impairment, however, would involve an obvious functional 
impact that is reasonably attributable to the problem. While functional impairment is likely to 
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have been present in individuals defined as cognitively impaired in the current paper, data on 
functional impairment was not collected. Further, this paper did not seek to determine the 
most clinically and functionally meaningful definition of cognitive impairment, but rather, to 
illustrate that groups categorised as ‘cognitively impaired’ can be vastly different depending 
on the approach used to define impairment. Certainly, future research to determine definitions 
that relate strongly to functional impairment will be integral to clinical trials that aim to 
improve cognitive and functional outcomes in mood disorder patients. In the area of 
psychotherapy research, Jacobson et al. (37) have suggested that clinically significant change 
may be the extent to which therapy moves an individual outside of the range of the 
‘dysfunctional’ population, or within the range of the ‘functional’ population. Definitions 
such as these may be useful to incorporate into discussion of approaches to categorising 
cognitive impairment in the future.  
 
Changes in Rates of Cognitive Impairment with Treatment 
In the inpatient depression sample, there was a difference in rates of impairment between 
responders and non-responders only when examining the domain of Psychomotor Speed. No 
treatment responders were impaired in this domain at 1.5 and 2 SD cut-offs at follow-up 
testing, while 18.2% and 3% of non-responders were impaired at these cut-offs, respectively. 
In the outpatient depression sample, after 16 weeks of weekly psychological therapy, there 
was no evidence of rates of cognitive impairment reducing in treatment responders compared 
with non-responders, in keeping with an analysis based on group means (9). 
 
These findings generally support studies suggesting limited effects of treatment, even when 
otherwise successful, on cognitive function (1, 7-10). Reduced rates of impairment in 
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psychomotor speed in the inpatient depression sample should be interpreted with caution 
since it was an isolated finding in this analysis. However, it is in accord with a previous study 
in an inpatient sample (38) and previous reviews have suggested that psychomotor speed may 
be the domain most likely to improve with successful treatment (1). 
 
Influence of Premorbid IQ on Rates of Cognitive Impairment 
In the current study, the Global Cognitive Composite was corrected to take into account the 
premorbid IQ of each participant. This then allowed determination of whether each 
participant was performing above or below their expected level of functioning on cognitive 
tests. Correction for premorbid IQ increased the number of participants categorised as 
cognitively impaired in the inpatient and outpatient depression samples (Study 1 and 2), 
significantly so for the inpatient sample. The higher prevalence in the inpatient sample was 
due to a substantial portion of participants with above average premorbid IQ (> 100) being 
re-categorised as impaired after correction for IQ. Objectively, these individuals did not show 
significant cognitive impairment in relation to healthy control norms, however, they were 
performing much more poorly than their premorbid IQ would have suggested. In line with 
this finding, research in late-life depression has found that individuals with high cognitive 
reserve show greater cognitive impairment as depressive symptoms increase, perhaps because 
they have ‘more to lose’ (39, 40). It is likely that these individuals have occupations that 
match their premorbid IQ level, and require strong cognitive skills. It is possible that patients 
who function at a relatively high level, and who develop severe depression, are more likely to 
become inpatients because of the social and occupational effects of being unable to cope with 
a reduction in cognitive capacity. This analysis emphasises the importance of taking 
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premorbid IQ into account, particularly when screening for cognitive impairment prior to 
commencing cognitive remediation interventions.  
 
Limitations 
First, because cognitive batteries differed, comparison of prevalence rates across groups has 
limited value. Of greater interest, however, was how prevalence rates varied within samples 
based on different definitions of impairment. Second, cut-offs for degree of impairment in the 
current paper used comparison with performance of matched healthy control groups rather 
than standardised norms. Healthy control group scores are likely to be more variable than 
standardised norms. On the other hand, using healthy control group norms may be a more 
accurate way of determining scores in a population of a particular age, gender and premorbid 
IQ, particularly because some less traditional tests used in the cognitive testing batteries in 
the current study had limited norm data available (e.g., the Simple Reaction Time Test in 
Studies 1 and 2, and the Consonant Vowel Consonant Verbal Learning Test in Study 2). It is 
worth noting, however, that norms from healthy control groups would not usually be used to 
inform screening in clinical trials of cognitive treatments. As discussed in Cullen et al.’s (11) 
review of prevalence of cognitive impairment in euthymic bipolar disorder, there is no clear 
association between choice of reference (e.g., standardised norms or healthy control groups) 
and prevalence rates of impairment. Some studies in Cullen’s review showed low prevalence 
rates using standardised norms compared with studies using comparison groups, while other 
studies showed some of the highest prevalence rates in bipolar disorder across cognitive 
domains when using standardised norms. Overall, it appears that choice of reference can 
impact on prevalence rates observed, and thus, this should be considered when comparing 
rates across studies. Third, there was substantial variability in the type of antidepressant 
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medication patients were treated with in the depressed inpatient sample (Study 1). This study 
was not a regimented treatment trial, but rather, a naturalistic study of treatment as usual in an 
inpatient setting. There is the suggestion that different classes of antidepressants may have 
differential impacts on cognitive function (41), and if so, cognitive findings in Study 1 may 
be limited by variability in treatment regimes. Such wide range in types of antidepressant 
medications prescribed meant that sub-analyses to examine differential effects of medications 
on cognitive function was not warranted. Of note, however, is that baseline analysis 
comparing cognitive performance of medicated and non-medicated patients did not produce 
any significant differences. In addition, a recent large-scale RCT (n = 1008) found no 
evidence that three types of antidepressant medication (escitalopram, venlafaxine or 
sertraline) differentially improved cognitive impairment over time (10).  
 
Limitations of using a word-reading test, such as the NART, as a measure of premorbid 
cognitive functioning should be noted. Evidence suggests the NART to be a reliable and valid 
proxy measure of general IQ, as well as being relatively resistant to the effects of psychiatric 
disorders (42). However, at a more conceptual level, using NART performance as an estimate 
of premorbid IQ, and then generalising this to performance on a broad range of cognitive 
tests (e.g., memory and executive function) may be overly simplistic. Incorporation of 
demographic variables (e.g., age, education level, SES) into a formula to estimate premorbid 
cognitive functioning may be more comprehensive, but to date, research has typically focused 
on such formulae to predict general IQ, rather than premorbid cognitive ability. Finally, it is 
possible that scores on the NART are affected by a phenomenon of lower cognitive 
performance in those susceptible to mood disorder.  This could be related either to a trait 
biological effect (43) or to adversity associated with parental mood disorder. 
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Implications and Conclusions 
The traditional presentation of cognitive data as group means of depressed versus control 
groups (or treatment responders versus non-responders) does not give a good indication of 
the numbers of participants in the sample with clinically significant cognitive impairment. 
Determining which individuals suffer from significant cognitive impairment is particularly 
important in treatment trials which will involve screening to improve cognitive outcomes 
(16). The specific definition of impairment used for screening depends to some degree on the 
type of cognitive remediation intervention used. For example, if a cognitive remediation 
intervention is to be tailored to an individual’s cognitive profile, then a definition that 
incorporates performance on each cognitive domain would be required. If a drug treatment 
known to have a side-effect burden was being trialed, then a particularly stringent definition 
of cognitive impairment would be most appropriate since this would only be used in 
individuals likely to gain very significant cognitive benefit. Thus, this current paper cannot 
provide a single recommendation for a method of screening for cognitive impairment. It has, 
however, highlighted the substantial variability in rates of cognitive impairment based on the 
definitions used and gives an indication of the percentages of different clinical groups who 
are likely to be classified as having impairment using these different definitions. This paper 
has also identified definitions of cognitive impairment that are less useful in mood disorder 
studies; the use of a definition based on a number of individual test results is less useful 
unless a set battery is used consistently. Furthermore, the study has highlighted the 
importance of taking into account premorbid IQ, particularly in individuals with severe 
depression. 
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Alongside the direct implications of findings from this paper is the question of who should be 
remediated in mood disorder samples. Typically, treatment decisions for mood symptoms are 
individualised to the patient. For example, if patients have a history of trauma, they are more 
likely to respond to therapy rather than medication (44). The same may be true for cognitive 
remediation, in that if patients have cognitive impairment, they are more likely to respond 
than those who are functioning well. Certainly, research indicates that individuals with the 
most severe cognitive impairment receive the greatest benefit from interventions aimed at 
improving cognitive outcomes (45). As in all clinical trials, there is a difficult balance 
between the imperative of the clinical trial – to produce a positive result, often achieved by 
selecting the most impaired patients, and the ability to develop treatments which may be 
effective across a range of impairment and are generaliseable. Impairments of 0.5 to 1 SD in 
key cognitive functions may still be disabling but statistically less likely to show differences 
between an investigational treatment and placebo.  
 
A related issue is that in MDD, psychological treatments based on cognitive activation may 
have positive effects on mood and cognition and therefore be potentially beneficial in 
individuals with milder cognitive impairment (46, 47). Allowing only those with serious 
cognitive impairment to partake in cognitive remediation interventions, thus, means that the 
majority of individuals with mood disorders will not have the opportunity to experience the 
activating effects on mood of repetitive cognitive training. The purpose of any proposed 
cognitive intervention, whether to activate or remediate, is important to consider prior to 
conducting screening procedures.  
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Table 1. Cognitive Tests Administered to the Four Mood Disorder Samples 
 
 Study 1 – inpatient depression Study 2 – outpatient depression Study 3 – bipolar depression Study 4 – euthymic bipolar 
Verbal Learning and 
Memory 
Rey Auditory-Verbal Learning Test Rey Auditory-Verbal Learning Test 
Consonant Vowel Consonant Verbal 
Learning Test 
Rey Auditory-Verbal Learning Test Rey Auditory-Verbal Learning Test 
 
Visuospatial Learning 
and Memory 
Groton Maze Learning Test (CogState©) Pattern Recognition Memory (CANTAB®) 
Spatial Recognition Memory (CANTAB®) 
 
Pattern Recognition Memory (CANTAB®) 
Spatial Recognition Memory (CANTAB®) 
 
Pattern Recognition Memory (CANTAB®) 
Spatial Recognition Memory (CANTAB®) 
Simultaneous and Delayed Match to Sample 
(CANTAB®) 
Paired Associates Learning (CANTAB®) 
Executive Function / 
Attention 
Stroop Test 
 
Controlled Oral Word Association Test 
Digit Span Forwards and Backwards 
Spatial Span (CANTAB®) 
Spatial Working Memory (CANTAB®) 
 
Controlled Oral Word Association Test 
Digit Span Forwards and Backwards 
Spatial Span (CANTAB®) 
Spatial Working Memory (CANTAB®) 
 
Controlled Oral Word Association Test 
Digit Span Forwards and Backwards  
Spatial Span (CANTAB®) 
Spatial Working Memory (CANTAB®) 
Stroop Test 
Trail Making Test Part B 
Vigil Test (errors) 
Tower of London (min. move solutions) 
Psychomotor Speed Simple Reaction Time Task 
Timed Chase Test (CogState©) 
Simple Reaction Time Task 
Motor Screening (CANTAB®) 
Digit Symbol Substitution Test Trail Making Test Part A 
Digit Symbol Substitution Test 
Vigil Test (response latency) 
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Table 2. Demographic Characteristics of Mood Disorder and Healthy Control Samples 
 
 Study 1  
Inpatient Depression 
Study 2  
Outpatient Depression 
Study 3 
Bipolar Depression 
Study 4 
Euthymic Bipolar Disorder 
 Patient (n=58) Control (n=50) Patient (n=69) Control (n=58) Patient (n=56) Control (n=53) Patient (n=63) Control (n=63) 
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Age 39.0 10.7 38.5 11.6 39.7 11.9 38.0 12.8 48.1 9.2 45.5 13.1 44.4 8.6 45.4 9.1 
Gender (male:female) 22:36 - 18:32 - 23:46 - 19:39 - 30:26 - 28:25 - 37:26 - 37:26 - 
Predicted verbal IQ 106.8 8.5 107.4 6.6 108.4 8.7 108.6 7.7 110.2 10.5 113.2 11.0 109.6 10.2 110.0 9.2 
Formal education  
(total years) 
13.1 2.5 13.1 1.9 13.9 2.4 13.8 2.5 14.5 3.3 14.8 4.3 14.2 3.0 14.2 3.1 
Note: no significant differences between clinical and corresponding healthy control samples were found for any variables 
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Table 3. Clinical Characteristics of the Four Mood Disorder Samples 
 
 Study 1  
Inpatient 
Depression  
(n=58) 
Study 2  
Outpatient 
Depression  
(n=69) 
Study 3 
Bipolar 
Depression  
(n=56) 
Study 4 
Euthymic Bipolar 
Disorder 
(n=63) 
 Mean SD Mean SD Mean SD Mean SD 
Baseline MADRS 35.7 8.8 23.4 6.3 27.2 7.3 - - 
Baseline HDRS17 - - 16.1 5.3 19.6 4.7 2.1 1.7 
Baseline YMRS - - - - 1.9 2.8 1.4 2.0 
Age at illness onset (years) 30.0 10.8 22.5 11.8 26.3 13.0 25.3 7.2 
Unipolar MDD:Bipolar Disorder 50:8 - 64:5 - 0:56 - 0:63 - 
No. depressive episodes  - - 3.9 4.4 - - 12.0 16.4 
No. previous hospitalisations 0.8 1.5 - - 3.1 4.2 5.0 6.1 
MADRS = Montgomery-Asberg Depression Rating Scale; HDRS17 = Hamilton Depression Rating Scale (17-item version); YMRS = Young Mania Rating Scale 
Note: a dash (-) refers to data not being available due to the item not being included in the study 
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Table 4. Prevalence (%) of Impairment using Four Approaches to Classify Cognitive 
Impairment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Study 1 
Inpatient 
Depression 
Study 2 
Outpatient 
Depression 
Study 3 
Bipolar 
Depression 
Study 4 
Euthymic 
Bipolar 
  Patient Control Patient Control Patient Control Patient Control 
Cognitive domains: number of domains impaired 
1 SD 
 No domains impaired 12.6 70.0 47.1 79.4 35.6 71.7 42.9 77.7 
 ≥ 1 domains impaired 87.4 30.0 52.9 20.6 64.4 28.3 57.1 22.3 
 ≥ 2 domains impaired 55.3 12.0 17.6 5.1 34.0 11.3 33.3 4.8 
 ≥ 3 domains impaired 26.7 4.0 4.4 3.4 19.7 3.8 17.4 1.6 
 4 domains impaired  7.1 0.0 2.9 0.0 1.8 0.0 7.9 0.0 
1.5 SD 
 No domains impaired 41.1 82.0 76.7 86.3 53.5 86.8 61.9 93.6 
 ≥ 1 domains impaired 58.9 18.0 23.3 13.7 46.5 13.2 38.1 6.4 
 ≥ 2 domains impaired 37.5 4.0 8.9 3.4 17.9 1.9 20.6 1.6 
 ≥ 3 domains impaired 7.1 0.0 1.5 1.7 5.4 0.0 11.1 0.0 
 4 domains impaired  0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 SD 
 No domains impaired 62.5 92.0 85.3 93.1 67.8 94.3 76.2 96.8 
 ≥ 1 domains impaired 37.5 8.0 14.7 6.9 32.2 5.7 23.8 3.2 
 ≥ 2 domains impaired 14.3 0.0 4.4 0.0 7.2 1.9 11.1 0.0 
 ≥ 3 domains impaired 0.0 0.0 0.0 0.0 1.8 0.0 3.2 0.0 
 4 domains impaired  0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Cognitive domains: percentage impaired on each domain 
Verbal learning and memory 
 ≥ 1.0 SD 51.7 10.0 36.2 8.6 39.3 9.4 19.4 11.1 
 ≥ 1.5 SD 36.2 4.0 17.4 5.2 23.2 3.8 12.7 3.2 
 ≥ 2.0 SD 15.5 2.0 8.7 1.7 12.5 1.9 4.8 1.6 
Visual spatial learning and memory 
 ≥ 1.0 SD 45.6 10.0 17.6 8.6 26.8 15.1 28.6 6.3 
 ≥ 1.5 SD 26.3 6.0 11.8 6.9 17.9 3.8 15.9 3.2 
 ≥ 2.0 SD 19.3 0.0 4.4 3.4 14.3 3.8 9.5 1.6 
Executive function / attention 
 ≥ 1.0 SD 50.9 14.2 8.8 1.7 16.1 3.8 30.2 1.6 
 ≥ 1.5 SD 34.0 4.1 1.5 0.0 5.4 0.0 14.3 1.6 
 ≥ 2.0 SD 15.1 4.1 0.0 0.0 0.0 0.0 9.3 0.0 
Psychomotor speed 
 ≥ 1.0 SD 33.9 12.0 14.7 10.3 37.5 15.1 38.7 9.5 
 ≥ 1.5 SD 14.3 8.0 7.4 6.9 23.2 7.5 29.0 1.6 
 ≥ 2.0 SD 3.6 2.0 4.4 1.7 14.3 1.9 14.5 0.0 
Global cognitive composite 
 ≥ 1.0 SD 45.3 4.1 11.8 3.4 28.6 7.5 30.2 3.2 
 ≥ 1.5 SD 18.9 0.0 2.9 0.0 12.5 1.9 14.3 1.6 
 ≥ 2.0 SD 7.5 0.0 1.5 0.0 0.0 0.0 3.2 0.0 
Individual cognitive variables 
 ≥ 1 SD on ≥ 2 test 
variables 
91.4 22.0 78.6 55.2 71.4 35.8 93.7 79.4 
 ≥ 1.5 SD on ≥ 2 test 
variables 
60.3 14.0 47.1 25.8 46.4 13.2 77.8 49.2 
 ≥ 2.0 SD on ≥ 2 test 
variables 
32.8 6.0 14.3 10.3 23.2 5.7 52.4 19.0 
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Table 5. Prevalence (%) of Impairment using Four Approaches to Define Cognitive Impairment in 
Relation to Treatment Response  
 
  Study 1 
Inpatient Depression 
  Study 2 
Outpatient Depression 
  
  
Response 
Non-
Response 
Control 
χ2/U 
P-
value 
Response 
Non-
Response 
Control 
χ2/U 
P-
value 
  (n = 25) (n = 33) (n = 50) (n = 37) (n = 32) (n = 58) 
Cognitive domains: number of domains impaired      
1 SD      
 No domains impaired 8.0 12.1 58.0 344.5 0.2a 56.8 53.1 67.3 573.5 0.8a 
 ≥ 1 domains impaired 92.0 87.9 42.0   43.2 46.9 32.7   
 ≥ 2 domains impaired 32.0 51.5 14.0   13.5 12.5 5.1   
 ≥ 3 domains impaired 16.0 27.3 6.0   0.0 3.1 1.7   
 4 domains impaired  4.0 12.1 2.0   0.0 0.0 0.0   
1.5 SD      
 No domains impaired 44.0 42.4 84.0 379.0 0.6a 78.4 65.6 94.9 508.5 0.2a 
 ≥ 1 domains impaired 40.0 57.6 16.0   21.6 34.4 5.1   
 ≥ 2 domains impaired 12.0 27.3 6.0   0.0 6.3 1.7   
 ≥ 3 domains impaired 4.0 9.1 2.0   0.0 0.0 0.0   
 4 domains impaired  0.0 3.0 0.0   0.0 0.0 0.0   
2 SD      
 No domains impaired 64.0 57.5 92.0 391.0 0.7a 86.5 84.4 94.9 577.0 0.8a 
 ≥ 1 domains impaired 28.0 42.5 8.0   13.5 15.6 5.1   
 ≥ 2 domains impaired 8.0 6.1 2.0   0.0 3.1 1.7   
 ≥ 3 domains impaired 0.0 0.0 0.0   0.0 0.0 0.0   
 4 domains impaired  0.0 0.0 0.0   0.0 0.0 0.0   
Cognitive domains: percentage impaired on each domain 
Verbal learning and memory 
 ≥ 1.0 SD 40.0 48.5 18.0 405.5 0.9a 35.1 40.6 12.1 540.5 0.5a 
 ≥ 1.5 SD 24.0 24.2 8.0   13.5 25.0 1.7   
 ≥ 2.0 SD 20.0 21.2 2.0   5.4 9.4 1.7   
Visual spatial learning and memory 
 ≥ 1.0 SD 58.3 42.4 16.0 329.0 0.2a 8.1 15.6 10.3 546.0 0.3a 
 ≥ 1.5 SD 37.5 21.2 2.0   2.7 9.4 1.7   
 ≥ 2.0 SD 4.2 9.1 2.0   2.7 6.3 1.7   
Executive function / attention 
 ≥ 1.0 SD 30.4 41.9 12.0 305.5 0.3a 0.0 0.0 6.9 592.0 1.0a 
 ≥ 1.5 SD 13.0 35.5 8.0   0.0 0.0 0.0   
 ≥ 2.0 SD 13.0 16.1 6.0   0.0 0.0 0.0   
Psychomotor speed 
 ≥ 1.0 SD 17.4 48.4 18.0 249.5 0.01a 13.9 6.3 12.1 534.0 0.3a 
 ≥ 1.5 SD 0.0 18.2 6.0   5.6 6.3 5.2   
 ≥ 2.0 SD 0.0 3.0 2.0   5.6 3.1 5.2   
Global Cognitive Composite      
 Impaired by ≥ 1.0 SD 27.3 45.2 10.0 1.8 0.2b 5.6 9.4 1.7 0.4 0.5b 
 Impaired by ≥ 1.5 SD 9.1 16.1 2.0 0.6 0.5b 2.8 3.1 1.7 - 0.5c 
 Impaired by ≥ 2.0 SD 4.5 3.2 2.0 - 1.0c 2.8 0.0 1.7 - - 
Individual Cognitive Variables      
 Impaired ≥ 1 SD on ≥ 2 
test variables 
51.8 78.8 24.0 0.4 0.6b 75.7 71.9 55.2 0.1 0.7b 
 Impaired ≥ 1.5 SD on ≥ 2 
test variables 
32.0 57.6 12.0 3.7 0.05b 27.0 40.6 19.0 1.4 0.2b 
 Impaired ≥ 2.0 SD on ≥ 2 
test variables 
16.0 39.4 8.0 3.8 0.05b 14.3 20.7 5.2 0.5 0.5b 
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Statistical comparisons were conducted between responders and non-responders for each sample 
a Mann-Whitney U test (testing the difference in distribution in number of domains impaired)  
b Pearson chi-square test 
c Fisher’s exact test (no statistical value available) 
 
38 
 
Figure Legend 
 
Figure 1. Percentage of mood disorder samples impaired at 1.5 SD cut-off on Global Cognitive 
Composite after correction for premorbid IQ (BD = bipolar disorder) 
* chi-square test, χ2 = 4.1, p = 0.04 
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